Continental Hospitals in Gachibowli, Hyderabad launched a cutting-edge biobank facility on November 10. This new research center will transform how scientists study diseases and develop treatments using artificial intelligence.
The Continental Next-Generation Biobank combines state-of-the-art storage systems with smart data technology. Scientists can now store biological samples more effectively while analyzing vast amounts of medical information through AI systems.
Chronicle Bio partnered with Continental Hospitals to create this advanced facility. Rohit Gupta, Chronicle Bio’s CEO, brings extensive experience from managing Stanford University’s biobank operations. His expertise helps ensure the facility meets world-class research standards.
The biobank will collect various biological samples from patients, including blood, tissue, and other specimens. These samples connect to anonymous patient data and genetic information. Researchers use this combined data to discover new ways diseases develop and spread.
Dr. Guru N Reddy, Continental Hospitals’ founder and chairman, emphasized the facility follows international guidelines for sample collection and storage. The biobank also maintains strict patient privacy standards, making it compatible with global research projects.
Several biotechnology companies have already started working with the new facility. Larger research programs will begin in 2026, expanding the biobank’s impact on medical discoveries.
Rishi Reddy, who serves as both Chronicle Bio co-founder and Continental Hospitals director, highlighted the biobank’s importance for cancer research and personalized medicine. These facilities help scientists create better diagnostic tools and targeted treatments.
The biobank connects India’s strong clinical research capabilities with international scientific networks. Partnerships with leading US institutions and global research centers will accelerate medical breakthroughs.
Scientists expect this facility to identify new disease markers and treatment targets more efficiently. The combination of diverse biological samples and advanced AI analysis will speed up the development of life-saving therapies.
